News

Moderna and CytomX Announce mRNA Partnership

January 10, 2023

The collaboration will see Moderna and CytomX work together to develop mRNA-based conditionally activated therapeutics.

FDA Grants Accelerated Approval for Eisai Alzheimer’s Disease Treatment

January 10, 2023

Eisai’s Alzheimer’s treatment, Leqembi (lecanemab-irmb), received approval from FDA via the Accelerated Approval pathway.

Astrea Bioseparations Acquires Delta Precision

January 09, 2023

Astrea Bioseparations has acquired Delta Precision, a manufacturer of chromatography columns for biomanufacturing.

Avantor and Catalent Enter Multi-Year Agreement

January 09, 2023

Avantor and Catalent have entered into a multi-year supply and services agreement.

FDA Policy Change Heightens Debate Over Medicated Abortion

January 05, 2023

The agency revised a regulation to enable pharmacies to dispense mifepristone directly to individuals with a prescription.

Agilent Acquires Life Sciences Company Avida Biomed

January 04, 2023

Agilent’s acquisition of Avida grants them access to high-performance enrichment workflows that enable NGS approaches for studying cancer.

Merck Licenses Kelun-Biotech ADC’s in Deal Worth $9.3 Billion

January 04, 2023

Merck, known as MSD outside of the United States and Canada, will pay Kelun-Biotech up to $9l3 billion for seven early-stage oncology treatments.

Opening Up Opportunities in 2023

January 03, 2023

Bio/pharma has evolved and adapted to a variety of challenges in 2022, but what might be on the cards for the industry in 2023?

Crossing the Same River Multiple Times

January 03, 2023

Cautiously setting aside pandemic practices, pharma workers appear ready for flux, change, evolution, and expanding molecular diversity.

Cleaning Up in Bio/Pharma

January 02, 2023

As the therapeutic landscape grows more complex, so too must the analytical techniques for cleaning validation to ensure the utmost cleanliness is achieved.